J. L. Goldstein et al. REFERENCES 1. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 32: 667–77. 2. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of non- steroidal antiinﬂammatory drugs. N Engl J Med 1992; 327: 749–54. 3. Lanas A, Sopena F. Nonsteroidal anti- inﬂammatory drugs and lower gastroin- testinal complications. Gastroenterol Clin North Am 2009; 38: 333–52. 4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8. 5. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81. 6. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Thera- peutic Arthritis Research and Gastroin- testinal Event Trial (TARGET), reduction in ulcer complications: rando- mised controlled trial. Lancet 2004; 364: 665–74. 7. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastro- intestinal complications in patients with rheumatoid arthritis receiving non- steroidal anti-inﬂammatory drugs. A randomized, double-blind, placebo-con- trolled trial. Ann Intern Med 1995; 123: 241–9. 8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celec- oxib vs nonsteroidal anti-inﬂammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247– 55. 9. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofe- nac in osteoarthritis patients: SUCCESS- I Study. Am J Med 2006; 119: 255–66. 10. Bjarnason I, O’Morain C, Levi AJ, Peters TJ. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inﬂamma- tory bowel disease. Gastroenterology 1983; 85: 318–22. 11. Chan FK, Hung LC, Suen BY, et al. Cel- ecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104–10. 12. Goldstein JL, Eisen GM, Lewis B, Gral- nek IM, Zlotnick S, Fort JG. Video cap- sule endoscopy to prospectively assess small bowel injury with celecoxib, nap- roxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–41. 13. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55–9. 14. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288–92. 15. Thieﬁn G, Beaugerie L. Toxic effects of nonsteroidal antiinﬂammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005; 72: 286–94. 16. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheuma- toid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173–9. 17. Chan FK, Cryer B, Goldstein JL, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of non- steroidal antiinﬂammatory drugs through the entire GI tract. J Rheumatol 2010; 37: 167–74. 18. FDA. Advisory Committee Brieﬁng Document. Available at: http://www.fda.- gov/ohrms/dockets/ac/01/brieﬁng/ 3677b1_05_gi.pdf. Accessed January 4, 2010. 19. Chaves PH, Xue QL, Guralnik JM, Fer- rucci L, Volpato S, Fried LP. What con- stitutes normal hemoglobin concentration in community-dwelling disabled older women? J Am Geriatr Soc 2004; 52: 1811–6. 20. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. Blood Rev 2006; 20: 213–26. 21. Penninx BW, Pluijm SM, Lips P, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 2005; 53: 2106–11. 22. Penninx BW, Pahor M, Woodman RC, Guralnik JM. Anemia in old age is asso- ciated with increased mortality and hos- pitalization. J Gerontol A Biol Sci Med Sci 2006; 61: 474–9. 23. FDA. Gastrointestinal Drug Advisory Committee Meeting. Available at: http:// www.fda.gov/down loads/AdvisoryCom- mittees/Committees MeetingMaterials/ Drugs/Gastrointestinal DrugsAdvisoryCommittee/ UCM231990.pdf. Accessed January 4, 2010. 24. Lanas A. A review of the gastrointestinal safety data–a gastroenterologist’s per- spective. Rheumatology (Oxford) 2010; 49(Suppl 2): ii3–10. 25. Penninx BW, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004; 52: 719–24. 26. Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omepra- zole, as assessed by video capsule endos- copy. Aliment Pharmacol Ther 2007; 25: 1211–22. 816 Aliment Pharmacol Ther 2011; 34: 808–816 ª 2011 Blackwell Publishing Ltd